April 30 , 2014 –  The U.S. Food and Drug Administration yesterday granted accelerated approval to Zykadia (ceritinib) for patients with a certain type of late-stage (metastatic) non-small cell lung cancer (NSCLC). Zykadia is an anaplastic lymphoma kinase (ALK) tyrosine kinase …

FDA approves the (ALK) tyrosine kinase inhibitor Ceritinib [Zykadia] for late-stage lung cancer Read more »